Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $829.07 million
- Book Value:
- Revenue TTM:
- $52.16 million
- Operating Margin TTM:
- Gross Profit TTM:
- $15.54 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Ardelyx Inc had its IPO on 2014-06-19 under the ticker symbol ARDX.
The company operates in the Healthcare sector and Biotechnology industry. Ardelyx Inc has a staff strength of 0 employees.
Shares of Ardelyx Inc opened at $4.11 at the start of the last trading session i.e. 2023-03-22.
The stocks traded within a range of $3.9 - $4.12, and closed at $3.92.
This is a -5.31% slip from the previous day's closing price.
A total volume of 5,648,055 shares were traded at the close of the day’s session.
In the last one week, shares of Ardelyx Inc have slipped by -0.76%.
Ardelyx Inc's Key Ratios
Ardelyx Inc has a market cap of $829.07 million, indicating a price to book ratio of 5.5233 and a price to sales ratio of 39.5354.
In the last 12-months Ardelyx Inc’s revenue was $52.16 million with a gross profit of $15.54 million and an EBITDA of $-56415000. The EBITDA ratio measures Ardelyx Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Ardelyx Inc’s operating margin was -110.36% while its return on assets stood at -21.16% with a return of equity of -74.28%.
In Q4, Ardelyx Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 4193.3%.
Ardelyx Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.14 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.08. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ardelyx Inc’s profitability.
Ardelyx Inc stock is trading at a EV to sales ratio of 35.063 and a EV to EBITDA ratio of -2.8787. Its price to sales ratio in the trailing 12-months stood at 39.5354.
Ardelyx Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $190.07 million
- Total Liabilities
- $65.60 million
- Operating Cash Flow
- $1.44 million
- Capital Expenditure
- Dividend Payout Ratio
Ardelyx Inc ended 2023 with $190.07 million in total assets and $0 in total liabilities. Its intangible assets were valued at $190.07 million while shareholder equity stood at $98.33 million.
Ardelyx Inc ended 2023 with $0 in deferred long-term liabilities, $65.60 million in other current liabilities, 20000.00 in common stock, $-780137000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $96.14 million and cash and short-term investments were $123.91 million. The company’s total short-term debt was $30,605,000 while long-term debt stood at $0.
Ardelyx Inc’s total current assets stands at $153.60 million while long-term investments were $0 and short-term investments were $27.77 million. Its net receivables were $7.73 million compared to accounts payable of $10.86 million and inventory worth $3.28 million.
In 2023, Ardelyx Inc's operating cash flow was $1.44 million while its capital expenditure stood at $55000.
Comparatively, Ardelyx Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Ardelyx Inc stock is currently trading at $3.92 per share. It touched a 52-week high of $4.16 and a 52-week low of $4.16. Analysts tracking the stock have a 12-month average target price of $6.87.
Its 50-day moving average was $3.29 and 200-day moving average was $1.78 The short ratio stood at 1.68 indicating a short percent outstanding of 0%.
Around 150.5% of the company’s stock are held by insiders while 3966.4% are held by institutions.
Frequently Asked Questions About Ardelyx Inc
Similar Industry Stocks (Biotechnology)
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.